Sequential intravesical gemcitabine and mitomycin C chemotherapy regimen in patients with non-muscle invasive bladder cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 28, Issue 5, 2010, Pages 510-514

  Breyer, Benjamin N ^a   Whitson, Jared M ^a   Carroll, Peter R ^a   Konety, Badrinath R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCG refractory; Bladder cancer; Gemcitabine; Intravesical chemotherapy; Mitomycin C

Indexed keywords

BCG VACCINE; GEMCITABINE; MITOMYCIN C;

ADULT; AGED; ARTICLE; BLADDER CANCER; BLADDER SPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CYSTECTOMY; DRUG EFFICACY; DRUG TOLERABILITY; DYSURIA; FEMALE; FOLLOW UP; HUMAN; INVASIVE CARCINOMA; KAPLAN MEIER METHOD; LOWER URINARY TRACT SYMPTOM; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RASH; RECURRENCE RISK;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MITOMYCIN; URINARY BLADDER NEOPLASMS;

EID: 77956274411     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2008.11.019     Document Type: Article

References (22)

1. Jemal A., Clegg L.X., Ward E., et al. Annual report to the nation on the status of cancer, 1975-2001, with a special feature regarding survival. Cancer 2004, 101:3-27.
2. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
3. Lamm D.L., Blumenstein B.A., Crawford E.D., et al. A randomized trial of intravesical doxorubicin and immunotherapy with bacille Calmette-Guerin for transitional-cell carcinoma of the bladder. N Engl J Med 1991, 325:1205-1209.
4. Joudi F.N., O'Donnell M.A. Second-line intravesical therapy vs. cystectomy for bacille Calmette-Guerin (BCG) failures. Curr Opin Urol 2004, 14:271-275.
5. Huncharek M., Kupelnick B. Impact of intravesical chemotherapy vs. BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: Meta-analytic re-evaluation. Am J Clin Oncol 2003, 26:402-407.
6. Huncharek M., Kupelnick B. The influence of intravesical therapy on progression of superficial transitional cell carcinoma of the bladder: A meta-analytic comparison of chemotherapy vs. bacillus Calmette-Guerin immunotherapy. Am J Clin Oncol 2004, 27:522-528.
7. Dalbagni G., Russo P., Bochner B., et al. Phase II trial of intravesical gemcitabine in bacille Calmette-Guerin-refractory transitional cell carcinoma of the bladder. J Clin Oncol 2006, 24:2729-2734.
8. Dalbagni G., Russo P., Sheinfeld J., et al. Phase I trial of intravesical gemcitabine in bacillus Calmette-Guerin-refractory transitional-cell carcinoma of the bladder. J Clin Oncol 2002, 20:3193-3198.
9. Au J.L., Badalament R.A., Wientjes M.G., et al. Methods to improve efficacy of intravesical mitomycin C: Results of a randomized phase III trial. J Natl Cancer Inst 2001, 93:597-604.
10. Hendricksen K., Witjes W.P., Idema J.G., et al. Comparison of three schedules of intravesical epirubicin in patients with non-muscle invasive bladder cancer. Eur Urol 2007.
11. Shelley M.D., Wilt T.J., Court J., et al. Intravesical bacillus Calmette-Guerin is superior to mitomycin C in reducing tumor recurrence in high-risk superficial bladder cancer: A meta-analysis of randomized trials. BJU Int 2004, 93:485-490.
12. Malmstrom P.U., Wijkstrom H., Lundholm C., et al. Five-year follow-up of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group. J Urol 1999, 161:1124-1127.
13. Rintala E., Jauhiainen K., Kaasinen E., et al. Alternating mitomycin C and bacillus Calmette-Guerin instillation prophylaxis for recurrent papillary (stages Ta to T1) superficial bladder cancer. Finn Bladder Group. J Urol 1996, 156:56-59. Discussion 59-60.
14. Witjes J.A., Caris C.T., Mungan N.A., et al. Results of a randomized phase III trial of sequential intravesical therapy with mitomycin C and bacillus Calmette-Guerin vs. mitomycin C alone in patients with superficial bladder cancer. J Urol 1998, 160:1668-1671. Discussion 71-2.
15. Greenberg R.E., Bahnson R.R., Wood D., et al. Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology 1997, 49:471-475.
16. Steinberg G., Bahnson R., Brosman S., et al. Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group. J Urol 2000, 163:761-767.
17. Moskovitz B., Meyer G., Kravtzov A., et al. Thermo-chemotherapy for intermediate or high-risk recurrent superficial bladder cancer patients. Ann Oncol 2005, 16:585-589.
18. Paroni R., Salonia A., Lev A., et al. Effect of local hyperthermia of the bladder on mitomycin C pharmacokinetics during intravesical chemotherapy for the treatment of superficial transitional cell carcinoma. Br J Clin Pharmacol 2001, 52:273-278.
19. Herman T.S., Teicher B.A., Jochelson M., et al. Rationale for use of local hyperthermia with radiation therapy and selected anticancer drugs in locally advanced human malignancies. Int J Hyperthermia 1988, 4:143-158.
20. Di Stasi S.M., Giannantoni A., Stephen R.L., et al. Intravesical electromotive mitomycin C vs. passive transport mitomycin C for high risk superficial bladder cancer: A prospective randomized study. J Urol 2003, 170:777-782.
21. Maymi JL SN, O'Donnell MA. Intravesical sequential gemcitabine-mitomycin chemotherapy as salvage treatment for patients with refractory superficial bladder cancer. In: Proceedings of the American Urologic Association National Meeting, Atlanta (GA), May 2006 [Abstract 840].
22. Friedrich M.G., Pichlmeier U., Schwaibold H., et al. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with bacillus Calmette-Guerin (BCG) in patients with non-muscle invasive bladder carcinoma. Eur Urol 2007, 52:1123-1129.